Form 4: Moderna Director Noubar Afeyan Sells Shares Worth Millions

Noubar Afeyan, a director at Moderna, sold a significant number of shares indirectly held through Flagship Ventures funds and Flagship Pioneering.

Summary

• On June 11, 2024, Noubar Afeyan, a director of Moderna, indirectly sold shares of Moderna stock.
• The sales were executed through entities including Flagship Ventures Fund IV, L.P., Flagship Ventures Fund IV-Rx, L.P., and Flagship Pioneering, Inc.
• A total of 163,649 shares were sold at a weighted average price of $148.2944, and 6,420 shares were sold at a weighted average price of $149.4038.
• Additionally, 31,531 shares were sold at $148.2944 and 1,232 shares were sold at $149.4038.
• Following these transactions, Afeyan indirectly holds 7,930,725 shares through Flagship Ventures Fund IV, 1,528,557 shares through Flagship Ventures Fund IV-Rx, and 3,924 shares through Flagship Pioneering, Inc.
• Afeyan directly holds 1,946,931 shares.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting transactions. The sentiment depends on the investor's interpretation of the insider selling activity. It could be seen as slightly negative if investors interpret it as a lack of confidence, or neutral if seen as routine portfolio management.

Industry Context

Insider sales are common and can be for various reasons, including portfolio diversification or personal financial planning. However, significant insider selling can sometimes be perceived negatively by investors.

Comparison to Industry Standards

• Comparing Afeyan's transactions to other directors' dealings in similar biotech companies would provide context.
• For example, if other directors in companies like BioNTech or Pfizer have recently sold shares, it might indicate a broader trend.
• Analyzing the size of the transactions relative to Afeyan's total holdings and Moderna's market capitalization is also important.
• A small percentage sale might be less concerning than a large-scale divestment.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially impacting the stock price.
• The impact on other stakeholders (employees, customers, etc.) is likely minimal unless the selling signals a larger strategic shift.

Key Dates